HER2 mutations define a distinct, therapeutically actionable subset of NSCLC. Trastuzumab deruxtecan (T-DXd) has demonstrated strong activity in clinical trials, but real-world data are limited.

Welcome! You are invited to join a webinar: ASCO Highlights Lung Cancer 2025. After registering, you will receive a confirmation email about joining the webinar.

Background: Pleural mesothelioma (PM) is a rare type of cancer with poor prognosis. Prognostic and predictive biomarkers could improve treatment strategies in these patients. Programmed death ligand 1...

Wien (OTS) - Noch immer sterben in Österreich jährlich rund 4.000 Menschen an einem Lungenkarzinom - bei rund 5.000 Neudiagnosen pro Jahr. Mit der OPAL-Studie untersucht das Karl Landsteiner Institu...